Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis

Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis

Item
http://www.wikidata.org/entity/Q36040002
The next steps in next-gen sequencing of cancer genomesChallenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare SystemFGFR1 Amplification Is Often Homogeneous and Strongly Linked to the Squamous Cell Carcinoma Subtype in Esophageal CarcinomaEconomic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South KoreaMaintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe.Stress-Induced EGFR Trafficking: Mechanisms, Functions, and Therapeutic Implications.Long-term disease stabilization following treatment with erlotinib in heavily pretreated patients with wild-type epidermal growth factor receptor non-small-cell lung carcinoma: Two case reports.Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China.Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer.The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China.Evaluation of calculating carboplatin dosage in carboplatin-pemetrexed therapy as the first-line therapy for Chinese patients with advanced lung adenocarcinoma.Cisplatin-induced non-canonical endocytosis of EGFR via p38 phosphorylation of the C-terminal region containing Ser-1015 in non-small cell lung cancer cells.Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China
P2860

Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis

Item
http://www.wikidata.org/entity/Q36040002
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Epidermal Growth Factor Recept ...... er: An Evidence-Based Analysis
@ast
Epidermal Growth Factor Recept ...... er: An Evidence-Based Analysis
@en
type
label
Epidermal Growth Factor Recept ...... er: An Evidence-Based Analysis
@ast
Epidermal Growth Factor Recept ...... er: An Evidence-Based Analysis
@en
prefLabel
Epidermal Growth Factor Recept ...... er: An Evidence-Based Analysis
@ast
Epidermal Growth Factor Recept ...... er: An Evidence-Based Analysis
@en
P1433
P1476
P2093
P2860
P304
P31
P433
P478
P577
P698
P932
P1433
P1476
Epidermal Growth Factor Recept ...... er: An Evidence-Based Analysis
@en
P2093
Medical Advisory Secretariat
P2860
P304
P31
P433
P478
P577
P698
P932